Pacira Bioscience Inc., a Parsippany-based provider of non-opioid pain management options, announced on Monday it has appointed Donald C. Manning to chief medical officer, effective immediately.
In his new role, Manning will report directly to David Stack, chairman and CEO of Pacira.
“We are delighted to have Don join our leadership team. Don’s deep domain expertise in both anesthesiology and pharmacology will be of great value as we advance the commercial and clinical development of our non-opioid pain management portfolio. His career-long focus on patient quality of care is an excellent fit with our vision and culture, which is dedicated to making a fundamental difference in patients’ lives,” Stack said.
Manning, who has more than 20 years of experience in biopharmaceutical leadership, most recently served as the chief medical officer at Adynxx Inc. Before that, he spent 14 years in the pharmaceutical industry including global head of analgesics development at Novartis, head of clinical development at Alpharma, vice president of medical affairs at King Pharma and executive vice president and chief medical officer at Shionogi Inc.
“I am excited to be joining a talented and dedicated leadership team and to be working on the cutting edge of innovative technologies to provide opioid-sparing pain management to patients across a variety of surgical and rehabilitative settings. I look forward to applying my experiences in the commercial and clinical development of novel pain management solutions to help solve the devastating medical complications associated with opioid misuse and abuse,” Manning said.